Pacira Pharmaceuticals (PCRX) Set to Announce Quarterly Earnings on Tuesday

Pacira Pharmaceuticals (NASDAQ:PCRX) is scheduled to announce its earnings results before the market opens on Tuesday, February 27th. Analysts expect the company to announce earnings of $0.11 per share for the quarter.

Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) opened at $30.15 on Tuesday. The firm has a market capitalization of $1,220.00, a price-to-earnings ratio of -23.02 and a beta of 1.88. Pacira Pharmaceuticals has a 12 month low of $29.35 and a 12 month high of $58.95. The company has a quick ratio of 6.24, a current ratio of 6.99 and a debt-to-equity ratio of 1.03.

Several equities research analysts recently weighed in on PCRX shares. HC Wainwright reaffirmed a “buy” rating and issued a $52.00 price target on shares of Pacira Pharmaceuticals in a research note on Thursday, November 9th. Jefferies Group reduced their price target on Pacira Pharmaceuticals to $52.00 and set a “buy” rating on the stock in a research note on Thursday, November 9th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $55.00 price target on shares of Pacira Pharmaceuticals in a research note on Friday, October 27th. Wedbush reissued a “buy” rating and issued a $80.00 target price on shares of Pacira Pharmaceuticals in a report on Monday, November 20th. Finally, BidaskClub raised Pacira Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, December 29th. Four analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the stock. Pacira Pharmaceuticals has an average rating of “Hold” and a consensus price target of $46.53.

In other news, CEO David M. Stack sold 28,885 shares of the company’s stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $40.19, for a total transaction of $1,160,888.15. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 6.60% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Earnings History for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply